Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.00 | -$0.00 | -$0.00 |
Biodexa Pharmaceuticals Plc last posted its earnings results on Friday, September 12th, 2025. The company reported $-205266.60334 earnings per share for the quarter, missing analysts' consensus estimates of $-0.00397 by $205266.59937. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Biodexa Pharmaceuticals Plc has generated $-115,700 earnings per share over the last year ($-115700 diluted earnings per share) and currently has a price-to-earnings ratio of -0. Biodexa Pharmaceuticals Plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, April 24th, 2026 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/12/2025 | Q2 2025 | -$0.00 | -$150,600.00 | -150600 | $0 | $0 |
| 12/31/2024 | Q4 2024 | N/A | -$36,500.00 | N/A | N/A | $0 |
| 06/30/2024 | Q2 2024 | N/A | -$79,200.00 | N/A | $13.43 K | $0 |
| 12/30/2023 | Q4 2023 | N/A | -$11,300.00 | N/A | N/A | $83.00 K |
| 06/29/2023 | Q2 2023 | N/A | -$21,900.00 | N/A | N/A | $298.00 K |
| 12/30/2022 | Q4 2022 | N/A | -$296,700.00 | N/A | N/A | $231.00 K |
| 06/29/2022 | Q2 2022 | N/A | -$197,600.00 | N/A | N/A | $468.00 K |
| 12/30/2021 | Q4 2021 | N/A | -$148,900.00 | N/A | N/A | $177.00 K |
| 06/29/2021 | Q2 2021 | N/A | -$203,600.00 | N/A | N/A | $401.00 K |
| 12/30/2020 | Q4 2020 | N/A | -$307,900.00 | N/A | N/A | $175.00 K |
| 06/29/2020 | Q2 2020 | N/A | -$5,623,700.00 | N/A | N/A | $168.00 K |
| 12/30/2019 | Q4 2019 | N/A | -$1,829,200.00 | N/A | N/A | $222.00 K |
| 06/29/2019 | Q2 2019 | N/A | -$14,268,600.00 | N/A | N/A | $452.00 K |
| 12/30/2018 | Q4 2018 | N/A | -$30,384,200.00 | N/A | N/A | $1.39 M |
| 06/29/2018 | Q2 2018 | N/A | -$18,146,600.00 | N/A | N/A | $549.00 K |
| 12/30/2017 | Q4 2017 | N/A | -$18,304,800.00 | N/A | N/A | $516.00 K |
| 06/29/2017 | Q2 2017 | N/A | -$19,489,800.00 | N/A | N/A | $473.00 K |
| 12/30/2016 | Q4 2016 | N/A | $25,904,100.00 | N/A | N/A | $-3,614,000 |
| 06/29/2016 | Q2 2016 | N/A | -$26,493,400.00 | N/A | N/A | $2.95 M |
| 12/30/2015 | Q4 2015 | N/A | -$16,806,600.00 | N/A | N/A | $1.05 M |
Biodexa Pharmaceuticals Plc has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, April 24th, 2026 based offlast year's report dates.
The conference call for Biodexa Pharmaceuticals Plc's latest earnings report can be listened to online.
The conference call transcript for Biodexa Pharmaceuticals Plc's latest earnings report can be read online.
Biodexa Pharmaceuticals Plc (:BDRX) has a recorded net income of $-5,729,000.Biodexa Pharmaceuticals Plc has generated $-115700 earnings per share over the last four quarters.
Biodexa Pharmaceuticals Plc (:BDRX) has a price-to-earnings ratio of -0 and price/earnings-to-growth ratio is 0.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED